Skip to main content

Renalytix plc

corporate_fare Company Profile

Renalytix plc

RNLXY·OTC·Industrial Applications And Services·CIK 0001811115

Renalytix develops and offers KidneyIntelX, a diagnostic platform that includes the kidneyintelX.dkd testing service. KidneyIntelX refers to the company's diagnostic platform and products developed from it, including a laboratory developed test offered across the United States from CLIA certified laboratories. The kidneyintelX.dkd specific testing service from this platform received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) on June 29, 2023. KidneyintelX.dkd is the first FDA-authorized in-vitro prognostic test. It combines blood biomarkers and an artificial intelligence-enabled algorithm to help assess the risk of progressive decline in kidney function in adults with type 2 diabetes and early-stage kidney disease. The test aims to identify patients most at risk for significant sustained decline in kidney function during the early stages of the disease. When used as intended, kidneyintelX.dkd can support decisions on medical interventions early in the disease process, potentially avoiding kidney failure that requires long-term dialysis or a kidney transplant. The current addressable market for kidneyintelX.dkd in the US is approximately 14 million patients with adult diabetes and diagnosed chronic kidney diseases. Globally, the addressable market is estimated to be 260 million patients. The kidneyintelX.dkd test received formal Medicare coverage in June 2024 at $950 per test and has also received coverage from several major insurance plans, including large state Blue Cross Blue Shield plans. The majority of US patients who meet the intended use for kidneyintelX.dkd are expected to be over 65 years old and covered by Medicare.

Renalytix plc (OTC:RNLXY) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 1 item for RNLXY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-02-23, rated 7/10. Recent SEC coverage for RNLXY spans SCHEDULE 13D/A.

Recent high-impact activity:

  • Major Investor Group Reduces Stake Below 5% Threshold

Short Interest & Short Volume

2.77 days to cover

FINRA reported short interest of 12,430 shares in RNLXY as of the October 30, 2026 settlement, a 3701.2% increase from the prior period — about 2.8 days to cover at its recent average daily volume. On November 19, 2026, 4.0% of RNLXY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,430 shares as of October 30, 2026
Change vs prior period▲ 3701.2%
Days to cover2.77 at avg daily volume of 4,482
Daily short volume (FINRA facilities)4.0% of 5,641 shares on November 19, 2026
5-day average short volume18.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$3.45 -1.43% today
52-week range · as of 2026-02-23 $2.55 – $112.14
Market cap
$46.94M
Volume
2.6K (0.7× avg)
3-mo avg 4K
Live data · 2026-11-21 06:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RNLXY - Latest Insights

RNLXY
Feb 23, 2026, 4:21 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $3.45 info
Change: +$0.804 (+30%) info
Market Cap: $46.943M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets